Suzhou Fushilai Pharmaceutical Co. Ltd. (301258) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Suzhou Fushilai Pharmaceutical Co. Ltd. stock ¥13.68, price ¥23.80, that is 42.5% below the price, quality 53 out of 100. Rating: strongly overvalued. Calculated from audited financials with 10 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
55‑month range ¥19.76 – ¥62.80 · fair‑value band ¥9.03 – ¥15.15 · the ¥23.80 price screens above the ¥13.68 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Suzhou Fushilai Pharmaceutical Co. in your weekly email
Every Wednesday you see whether Suzhou Fushilai Pharmaceutical Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Suzhou Fushilai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and health care raw materials in China and internationally.
Show moreShow less
The company offers lipoic acid products comprising granular alpha lipoic acid, R-lipoic acid, r-lipoic acid tromethamine salt, and 6,8-dichlorooctanoic acid ethyl ester; l-carnosine; phosphatidylcholine products, which include glycerylphosphatidylcholine; and erelcoxib API, a nonsteroidal anti-inflammatory analgesic used to relieve the pain symptoms of osteoarthritis.
Its products are used in medicines, dietary supplements, and cosmetics applications. The company also engages in research and experimental development and capital market activities. The company exports its products to Europe, America, and Southeast Asia.
Suzhou Fushilai Pharmaceutical Co., Ltd. was founded in 2000 and is based in Changshu, China.
Stock analysis
Suzhou Fushilai Pharmaceutical Co. Ltd. (301258) currently trades at ¥23.80, while our model-based Fair Value estimate is ¥13.68, 43% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Economic Profit group reads highest at a median of ¥14.35 per share, and 1 of the 10 models we run sit above the ¥23.80 price.
Bear case: the Earnings-Based group reads lowest at ¥5.83, and 9 of the 10 models stay below the price. Data coverage for this calculation is low.
Scenario range: ¥9.03 (bear) to ¥15.15 (bull), the price of ¥23.80 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Suzhou Fushilai Pharmaceutical Co. Ltd. reported revenue of 433M CNY in FY2025 versus 522M CNY in FY2021, a compound −4.6%/yr. Reported net income was 64.3M CNY in FY2025, compounding −14.5%/yr from FY2021.
Key figures
Market cap 2.2B CNY (≈ $327M) Small · P/S ratio 5.97 · EPS (TTM) ¥−0.5300 · Dividend yield 0.9% · Net margin −12.6% · Return on equity −2.5% · Return on assets (EBIT) 5.4% (5-year average) · Operating margin −16.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 18 out of 100 (low confidence).
What moves the price
The share trades about 36% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −43%, 301258 screens richer than that median.
Fair Value models
Bear¥9.03Fair Value ¥13.68Bull¥15.15
Price ¥23.80 · Downside -42.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.14/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+0.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.9%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.7%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−18.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−19.3%
Dividend (yield on the price)0.9%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.35% → −2%
Compare Suzhou Fushilai Pharmaceutical Co. Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score53 · Above median
Fair Value upside−42.5% · Above median
Profitability
Return on assets3.0% · Above median
Net margin (12 months)−12.6% · Below median
Operating margin (12 months)−16.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−19.4% · Bottom 25%
Dividend yield (12 months)0.9% · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B1.17× · Cheaper than median
P/S (12 months)5.82× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)18· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Suzhou Fushilai Pharmaceutical Co. Ltd. (301258) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of ¥13.68 versus a price of ¥23.80, about 43% lower (overvalued).
What is the fair value of 301258?
Our model-based fair value for Suzhou Fushilai Pharmaceutical Co. Ltd. is ¥13.68 (as of Nov 5, 2026), built from audited fundamentals. The current price: ¥23.80.
What is the quality score of 301258?
Suzhou Fushilai Pharmaceutical Co. Ltd. has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Suzhou Fushilai Pharmaceutical Co. Ltd. (301258)?
Our model-based price target is the fair value of ¥13.68 (as of Nov 5, 2026) from 10 valuation models. Cautious scenario ¥9.03, optimistic scenario ¥15.15. It is a calculation from audited fundamentals, not an analyst target.
What is the Suzhou Fushilai Pharmaceutical Co. Ltd. stock forecast for 2026?
Our models put fair value at ¥13.68, about 43% lower versus a price of ¥23.80 (overvalued). Cautious scenario ¥9.03, optimistic scenario ¥15.15. The calculation is refreshed regularly with new filings.
What is the revenue of Suzhou Fushilai Pharmaceutical Co. Ltd. (301258)?
Suzhou Fushilai Pharmaceutical Co. Ltd. reported trailing-twelve-month revenue of about 375M CNY (latest available figure, as of Nov 5, 2026).
Does Suzhou Fushilai Pharmaceutical Co. Ltd. pay a dividend?
Suzhou Fushilai Pharmaceutical Co. Ltd. currently shows a dividend yield of 0.92% relative to its recent price (as of Nov 5, 2026).
How much is the dividend of Suzhou Fushilai Pharmaceutical Co. Ltd. (301258) and when is the ex-dividend date?
Suzhou Fushilai Pharmaceutical Co. Ltd. pays a dividend of ¥0.22 per share a year, a dividend yield of 0.9%. The last ex-dividend date was May 29, 2026. A dividend has been paid every year since at least 2022. The payout ratio is 31.4% of earnings. Our assessment: Token dividend. At a yield of 0.9% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.9% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.
What is the intrinsic value of Suzhou Fushilai Pharmaceutical Co. Ltd. (301258)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Suzhou Fushilai Pharmaceutical Co. Ltd. it is ¥13.68 per share (as of Nov 5, 2026), against a price of ¥23.80. It is the blended result of 10 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Suzhou Fushilai Pharmaceutical Co. Ltd. stock overvalued or undervalued in 2026?
As of Nov 5, 2026, 301258 trades above its calculated fair value: price ¥23.80, fair value ¥13.68, a gap of about −43% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 301258?
No. The price is what the market pays today (¥23.80); the fair value is what the company's own numbers justify (¥13.68). For Suzhou Fushilai Pharmaceutical Co. Ltd. the two are ¥10.12 per share apart. That gap is exactly why we show both numbers side by side.
How much is Suzhou Fushilai Pharmaceutical Co. Ltd. worth?
The market values Suzhou Fushilai Pharmaceutical Co. Ltd. at about 2.2B CNY (market capitalisation, as of Nov 5, 2026). Per share that is ¥23.80; our models calculate a fair value of ¥13.68 per share.
What do the bullish and bearish scenarios say about 301258?
Our models span a range for Suzhou Fushilai Pharmaceutical Co. Ltd.: cautious scenario ¥9.03, base ¥13.68, optimistic ¥15.15 per share (as of Nov 5, 2026, price ¥23.80). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Suzhou Fushilai Pharmaceutical Co. Ltd. (301258)?
Balance-sheet figures for Suzhou Fushilai Pharmaceutical Co. Ltd. (as of Nov 5, 2026): return on equity −2.5%. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is 301258 from its 52-week high?
Suzhou Fushilai Pharmaceutical Co. Ltd. trades at ¥23.80, about 36% below its 52-week high of ¥37.05 and 9% above the low of ¥21.91 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥13.68 is for.
Which stocks are comparable to Suzhou Fushilai Pharmaceutical Co. Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Suzhou Fushilai Pharmaceutical Co. Ltd. stock attractive at the current price?
The data as of Nov 5, 2026: price ¥23.80, calculated fair value ¥13.68 (−43%), Quality Score 53/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 301258 calculated?
We run Suzhou Fushilai Pharmaceutical Co. Ltd. through 10 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥13.68 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Suzhou Fushilai Pharmaceutical Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Suzhou Fushilai Pharmaceutical Co. Ltd. (301258)?
The closing price on Nov 6, 2026 was ¥23.80. Our model-based fair value is ¥13.68, about 43% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Suzhou Fushilai Pharmaceutical Co. Ltd. right now?
The price sits above even our optimistic bull case (¥15.15). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Suzhou Fushilai Pharmaceutical Co. Ltd.
How large is the market capitalisation of Suzhou Fushilai Pharmaceutical Co. Ltd. (301258)?
The market capitalisation of Suzhou Fushilai Pharmaceutical Co. Ltd. is 2.2B CNY (≈ $327M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Suzhou Fushilai Pharmaceutical Co. Ltd. (301258)?
The price-to-sales ratio of Suzhou Fushilai Pharmaceutical Co. Ltd. is 5.97 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Suzhou Fushilai Pharmaceutical Co. Ltd. (301258)?
Earnings per share at Suzhou Fushilai Pharmaceutical Co. Ltd. are ¥−0.5300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Suzhou Fushilai Pharmaceutical Co. Ltd. (301258)?
The dividend yield of Suzhou Fushilai Pharmaceutical Co. Ltd. is 0.9%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Suzhou Fushilai Pharmaceutical Co. Ltd. (301258)?
The net margin of Suzhou Fushilai Pharmaceutical Co. Ltd. is −12.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Suzhou Fushilai Pharmaceutical Co. Ltd. (301258)?
The return on equity (ROE) of Suzhou Fushilai Pharmaceutical Co. Ltd. is −2.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Suzhou Fushilai Pharmaceutical Co. Ltd. (301258)?
On an EBIT basis the return on assets of Suzhou Fushilai Pharmaceutical Co. Ltd. is 5.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Suzhou Fushilai Pharmaceutical Co. Ltd. (301258)?
The operating margin of Suzhou Fushilai Pharmaceutical Co. Ltd. is −16.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Suzhou Fushilai Pharmaceutical Co. Ltd. (301258)?
Revenue at Suzhou Fushilai Pharmaceutical Co. Ltd. is growing −19.4% versus a year earlier (3y avg −8.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Suzhou Fushilai Pharmaceutical Co. Ltd. (301258)?
Earnings per share at Suzhou Fushilai Pharmaceutical Co. Ltd. are growing +116% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Suzhou Fushilai Pharmaceutical Co. Ltd. (301258) generate?
The free cash flow of Suzhou Fushilai Pharmaceutical Co. Ltd. is −79.9M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch Suzhou Fushilai Pharmaceutical Co. Ltd. in the live analysis
One click puts Suzhou Fushilai Pharmaceutical Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 5, 2026